A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 According to an Oncolytics Biotech media release, data from this trial will be presented at the 2017 BIO Investor Forum.
    • 19 Sep 2017 According to an Oncolytics Biotech media release, survival data from the study will be presented at the at the Phacilitate Immuno-Oncology Frontiers Conference.
    • 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top